Therefore, as the GLP-1 RAs expand into non-T2DM indications such as obesity metabolic syndrome and other related conditions, controlled studies and better understanding of the molecular mechanisms of action are necessary to investigate this association and prevent potential serious consequences. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.